GlassScriptPhysician profile
Frederman Concepcion
NPI 1417181116
$118,110.57
in general payments reported to CMS, 2019-2025
20 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $7,335 · 2021: $19K · 2022: $20K · 2023: $14K · 2024: $4,180 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $2,300 · Travel and Lodging: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,425.00 |
| Food and Beverage | $2,300.16 |
| Travel and Lodging | $328.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $75,248.19 | 2019-2025 | Definity |
| Astellas Pharma US INC | $39,155.69 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $838.33 | 2019-2023 | Xarelto |
| Amgen INC. | $609.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $565.93 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $361.81 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $350.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.00 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $238.90 | 2023-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $108.11 | 2021-2023 | Onpattro |
| Boston Scientific Corporation | $75.84 | 2020-2025 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $75.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $30.19 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $25.52 | 2019 | |
| Edwards Lifesciences Corporation | $23.75 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $20.61 | 2024 | Arcalyst |
| Abbott Laboratories | $19.90 | 2023 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.57 | 2023 | Jardiance |
| Jazz Pharmaceuticals INC. | $14.49 | 2021 | |
| Amarin Pharma, INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederman Concepcion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.